Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

BACKGROUND: Parkinson's disease (PD) and its progression are thought to be caused and driven by misfolding of α‐synuclein (ASYN). UCB0599 is an oral, small‐molecule inhibitor of ASYN misfolding, aimed at slowing disease progression. OBJECTIVE: The aim was to investigate safety/tolerability and...

Descripción completa

Detalles Bibliográficos
Autores principales: Smit, Johan Willem, Basile, Peter, Prato, Maria Key, Detalle, Laurent, Mathy, François‐Xavier, Schmidt, Astrid, Lalla, Marianna, Germani, Massimiliano, Domange, Coralie, Biere, Anja‐Leona, Bani, Massimo, Carson, Stan, Genius, Just
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804489/
https://www.ncbi.nlm.nih.gov/pubmed/35959805
http://dx.doi.org/10.1002/mds.29170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804489/
https://www.ncbi.nlm.nih.gov/pubmed/35959805
http://dx.doi.org/10.1002/mds.29170

Ejemplares similares